Mylan (MYL) Receives Hold Rating from Mizuho

Mizuho reissued their hold rating on shares of Mylan (NASDAQ:MYL) in a research note released on Tuesday, TipRanks reports.

Several other brokerages have also commented on MYL. Zacks Investment Research lowered shares of Mylan from a strong-buy rating to a hold rating in a research report on Wednesday, January 23rd. UBS Group lowered shares of Mylan from a buy rating to a neutral rating and lowered their price objective for the stock from $54.00 to $32.00 in a research report on Wednesday, January 23rd. BidaskClub raised shares of Mylan from a strong sell rating to a sell rating in a research report on Tuesday, April 30th. Morgan Stanley raised shares of Mylan from an equal weight rating to an overweight rating and set a $35.00 price objective on the stock in a research report on Wednesday, March 6th. They noted that the move was a valuation call. Finally, Wells Fargo & Co lowered shares of Mylan from an outperform rating to a market perform rating and lowered their price objective for the stock from $33.00 to $22.00 in a research report on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $37.35.

MYL opened at $19.64 on Tuesday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.85 and a current ratio of 1.51. Mylan has a fifty-two week low of $19.40 and a fifty-two week high of $42.50. The stock has a market cap of $10.42 billion, a P/E ratio of 4.29, a PEG ratio of 1.05 and a beta of 1.44.

Mylan (NASDAQ:MYL) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.03. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The company had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same period last year, the firm earned $0.96 earnings per share. The firm’s revenue was down 7.0% on a year-over-year basis. Equities research analysts predict that Mylan will post 4.28 EPS for the current fiscal year.

In other news, insider Paul Campbell sold 11,533 shares of Mylan stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $27.50, for a total value of $317,157.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.81% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vicus Capital grew its stake in Mylan by 5.3% during the first quarter. Vicus Capital now owns 7,874 shares of the company’s stock valued at $223,000 after acquiring an additional 396 shares in the last quarter. Pinnacle Bank grew its stake in Mylan by 66.4% during the first quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock valued at $30,000 after acquiring an additional 423 shares in the last quarter. NuWave Investment Management LLC grew its stake in Mylan by 18.1% during the fourth quarter. NuWave Investment Management LLC now owns 3,136 shares of the company’s stock valued at $86,000 after acquiring an additional 480 shares in the last quarter. Global Retirement Partners LLC grew its stake in Mylan by 107.1% during the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock valued at $27,000 after acquiring an additional 500 shares in the last quarter. Finally, Gilman Hill Asset Management LLC grew its stake in Mylan by 3.6% during the fourth quarter. Gilman Hill Asset Management LLC now owns 15,142 shares of the company’s stock valued at $415,000 after acquiring an additional 525 shares in the last quarter. Hedge funds and other institutional investors own 83.69% of the company’s stock.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

See Also: Trading Ex-Dividend Strategy

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.